1910 GENETICS INC.
AI-driven drug discovery platform for selective calpain-1 inhibitor molecules targeting chronic pain
- Sector
- Biotech
- Headquarters
- Boston, MA
- Founded
- 2018
- Latest Form D
- $25.7M, Apr 2021
- Total capital
- $26.3M
- Federal grants
- $546K
- 1 award · 2021
- Rank in peer group#218 of 502
- Private capital raised
- $25.7M
- 1 Form D · last Apr 2021
- 66 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of selective calpain-1 inhibitors for chronic pain$546K
- Private capital raisedForm D · SEC · 1st filing$25.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#218 · top 43%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jennifer O. NwankwoResearcherExecutive Officer, DirectorLinked by $546K in grants as PI
- Jory O. BellDirectorNamed in SEC Form D filings
- Marc O. FosterDirectorNamed in SEC Form D filings
- Samir O. KumarDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingSubstituted Pyrimidine Compounds As TYK2 InhibitorsUSPTOApplication 19039366
- PendingKeto Amide Compounds As Calpain InhibitorsUSPTOApplication PCTUS2025057360
- PendingKeto Amide Compounds As Calpain InhibitorsUSPTOApplication 63726193
Show all 5 patent records
- Substituted Pyrimidine Compounds As TYK2 InhibitorsAug 14, 2025 · Application 19039366Pending
- Keto Amide Compounds As Calpain InhibitorsApplication PCTUS2025057360Pending
- Keto Amide Compounds As Calpain InhibitorsApplication 63726193Pending
- Substituted Pyrimidine Compounds As TYK2 InhibitorsApplication PCTUS2023071157Pending
- Substituted Pyrimidine Compounds As TYK2 InhibitorsApplication 63369760Pending
Related companies, and why
- REVEL PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- ADRX, INC.Similar federal contract value in Biotech · null in contracts
- TRANSCODE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- ELYSIUM THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- NEUROGT INCSimilar federal contract value in Biotech · null in contracts
- BLACKFYNN, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .